3.8 Article

A Case Report of COVID-Associated Catastrophic Antiphospholipid Syndrome Successfully Treated with Eculizumab

Related references

Note: Only part of the references are listed.
Article Cardiac & Cardiovascular Systems

Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2

Shiyu Yin et al.

Summary: This study compared coagulation features and clinical outcomes of patients with severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. The 28-day mortality rate was higher in the COVID group, which had older patients with higher platelet counts. Patients with markedly elevated D-dimer in the COVID group may benefit from anticoagulant treatment.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2021)

Article

Catastrophic antiphospholipid syndrome

Ignasi Rodriguez-Pintó et al.

Revista Colombiana de Reumatologia (2021)

Article Cardiac & Cardiovascular Systems

Successful outcome with eculizumab treatment in a patient with antiphospholipid syndrome presenting with an unusual thrombotic storm

Jones T. Nauseef et al.

Summary: This case study highlights the successful management of CAPS using eculizumab in a 54-year-old male patient, resulting in rapid and sustained resolution of lesions without recurrence.

JOURNAL OF THROMBOSIS AND THROMBOLYSIS (2021)

Review Immunology

Complement Inhibition and COVID-19: The Story so Far

Sofiane Fodil et al.

Summary: ARDS is the most severe complication of COVID-19 caused by the SARS CoV-2 virus. The complex mechanisms of progression from asymptomatic disease to pneumonia and ARDS are not fully understood but may involve the activation of the complement cascade. Studies have shown that complement inhibition could potentially attenuate inflammation, restore coagulation/fibrinolysis balance and improve organ function, potentially saving lives. Ongoing trials aim to clarify the benefit to risk profile of complement inhibitors and optimal targets in the complement cascade.

IMMUNOTARGETS AND THERAPY (2021)

Article Rheumatology

Antiphospholipid Antibodies in Critically Ill Patients With COVID-19

Meng Xiao et al.

ARTHRITIS & RHEUMATOLOGY (2020)

Article Rheumatology

Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications

Joan T. Merrill et al.

NATURE REVIEWS RHEUMATOLOGY (2020)

Review Orthopedics

COVID-19, Antiphospholipid Antibodies, and Catastrophic Antiphospholipid Syndrome: A Possible Association?

Georges El Hasbani et al.

CLINICAL MEDICINE INSIGHTS-ARTHRITIS AND MUSCULOSKELETAL DISORDERS (2020)

Review Medicine, Research & Experimental

Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature

Maria Giulia Tinti et al.

CLINICAL AND EXPERIMENTAL MEDICINE (2019)

Article Rheumatology

Role of Infectious Diseases in the Antiphospholipid Syndrome (Including Its Catastrophic Variant)

Claudia Mendoza-Pinto et al.

CURRENT RHEUMATOLOGY REPORTS (2018)

Article Education, Scientific Disciplines

The rheumatoloay/hematology interface: CAPS and MAS diagnosis and management

John M. Gansner et al.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2018)

Review Rheumatology

Treatment of catastrophic antiphospholipid syndrome

Nayef M. Kazzaz et al.

CURRENT OPINION IN RHEUMATOLOGY (2016)

Review Medicine, General & Internal

Antiphospholipid syndrome

S Gezer

DM DISEASE-A-MONTH (2003)